Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal cancer

BIG BANG: binimetinib, encorafenib, and cetuximab in BRAF non-V600E mutated mCRCПодробнее

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal CancerПодробнее

BREAKWATER: encorafenib plus cetuximab in patients with BRAF V600E-mutant mCRCПодробнее

Carcinoma del colon-retto BRAF-mutato, nuove evidenze dallo studio BEACONПодробнее

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal CancerПодробнее

CRC highlights from ESMO WCGIC 2021Подробнее

Encorafenib & Binimetinib + Cetuximab for Untreated BRAF V600E-Mutant Metastatic Colorectal CancerПодробнее

Real-World Management of Patients with BRAF-V600E mCRCПодробнее

First-Line Triplet in BRAF+ mCRCПодробнее

Jeffrey A. Meyerhardt, MD, considers the BEACON study in BRAF mutated metastatic colorectal cancerПодробнее

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal CancerПодробнее

Dr. Lenz on Breakthrough Designation of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRCПодробнее

Encoranefib, Binimetinib, and Cetuximab in BRAF V600E mutated colorectal cancerПодробнее

Dr. Bekaii-Saab on Tolerability of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRCПодробнее

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic ...Подробнее